Introduction

Diabetes is a worldwide health problem with a close link exists between diabetes and cardiovascular disease (CVD), whereas CVD is the most prevalent cause of mortality and morbidity among the diabetic populations (1). The prevalence of type 2 diabetes mellitus (T2DM) has been globally growing rapidly. Approximately 592 million people worldwide will become diabetic by the year 2035, with a universal prevalence of 10.1% (2).

Currently, the orally employed anti-diabetic agents: biguanides (e.g., metformin), sulfonylureas (e.g., glimepiride), α-glycosidase inhibitors (e.g., acarbose) and thiazolidinediones (e.g., pioglitazone), act to regulate a specific pathological pathway (3). Metformin has been utilised for 50 years and approved by the US Food and Drug Administration (FDA) in 1994. Moreover, most guidelines all over the world have recommended metformin as the first-line treatment for T2DM patients (4). Glimepiride is a second-generation sulfonylurea
that stimulates pancreatic β-cells to release insulin and it has been shown to act through additional extrapancreatic mechanisms. In addition, metformin is preferentially selected for combination therapy with sulfonylurea or insulin to achieve the glycemic target in patients who are not satisfactorily controlled by monotherapy alone (5).

Oxidative stress and inflammation contribute to the development of diabetic complications. Intracellular hyperglycemia promotes the production of mitochondrial reactive oxygen species (ROS). ROS is directly increase the expression of inflammatory factors, the formation of oxidised-low density lipoprotein, and insulin resistance (6). Depletion of blood glutathione (GSH) has been recorded in many clinical issues including T2DM (7). Kumawat et al. revealed that hyperglycemia induces oxidative stress through increasing the malondialdehyde (MDA) levels in diabetic patients (8). Moreover, oxidative stress produced from an imbalance between free radicals and the body’s antioxidant defense systems leads to red blood cell dysfunction and tissue injury (9).

Recently, a great attention re-given to the hematological indices as predictors of endothelial dysfunction and inflammation status (10). Anemia is twice in diabetic patients, and mild anemia also has been recorded in diabetics with normal kidney function (11). In addition, anemia is associated with duration of disease and microvascular complications; diabetic neuropathy, nephropathy, retinopathy and CVD (12). Red blood cells (RBCs) count is a pivotal marker for the ability to recognise diabetic patients at risk of microvascular complications. Lower RBCs counts are, therefore, considered as an independent predictor biomarker of the risk of microvascular complications in T2DM patients (13). Additionally, erythrocytes of diabetic patients aggregate more readily that is obviously enhance whole-blood viscosity (WBV), and adversely influence the microcirculation and finally leading to microangiopathy (14).

Among RBCs indices, the red blood cell distribution width (RDW) is a simple and non-expensive parameter, which can reflect the level of erythrocyte volume heterogeneity (anisocytosis) and is commonly used in the laboratory for differential analysis of anemia (15). Furthermore, RDW values showed a significant increase in T2DM patients than in control subjects (16). Thus, the ideal therapy for diabetes would be a medication that besides its hypoglycemic effect can reduce the oxidation status and diabetic complications. Consequently, the goal of our study was to evaluate the impact of metformin administration (mono- and dual therapy) and glycemic control on RBC indices alterations and oxidative stress status in Egyptian patients with T2DM.

**Subjects and Methods**

**Patients Inclusion and Exclusion Criteria**

The study was conducted on 158 individuals of both sexes (83 males and 75 females), aged between 30 and 75 years. These individuals enrolled in this study were classified into 50 normal healthy subjects and 108 T2DM patients who were followed up at the Diabetic Section of General Institution of Healthy Insurance, Egypt, between December 2016 to October 2017. Written agreements were obtained from all patients before participation in the study. The present study was performed in accordance with the declaration of Helsinki and good clinical practice guidelines and also approved by the committee of General Institutions of Health Insurance.

Enrolled patients were allocated to normal healthy subjects (control) who had no previous history of chronic diseases and free of type 1 or 2 diabetes, and 108 patients diagnosed as T2DM according to WHO 1999 criteria. Pregnant and lactating women, patients receiving immuno-modulatory drugs and patients with medical conditions such as infections, cerebrovascular diseases, ischemic heart disease, malignancies, autoimmune disorders, eczema, respiratory disorder, thyroid dysfunction, kidney failure, liver dysfunction and alcohol abuse were excluded from the study. In addition, diabetic patients who underwent medication changes during the 2 months preceding participation were also excluded.

**Study Design**

The diabetic patients were subdivided into six groups according to the treatment administration.

1. **Group 1**: normal healthy subjects (control) (50 subjects)
2. **Group 2**: diabetics (recent diagnoses) non-treated (20 patients)
3. **Group 3**: diabetics treated with metformin only (15 patients)
4. Group 4: diabetics treated with glimepiride only (19 patients)
5. Group 5: diabetics treated with metformin + glimepiride (15 patients)
6. Group 6: diabetics treated with insulin only (20 patients)
7. Group 7: diabetics treated with metformin + insulin (19 patients)

The demographic data regarding anthropometric variables such as height, weight, body mass index (BMI), gender, duration of disease and blood pressure (BP) were collected. Blood samples were taken from participants after overnight fasting in EDTA and plain tubes (4 mL each). Following an incubation period of 30 min at room temperature, blood in plain tubes was centrifuged at 4,000 g for serum isolation. Sera were rapidly separated, aliquoted and stored at −40 °C until the biochemical measurements. The second tube blood sample was taken on potassium fluoride for immediate glucose estimation. The third part of the blood sample was taken on EDTA for determination of HbA1c levels and complete blood picture at the same time, then, the blood was centrifuged, the plasma and leucocytes layer were then removed and the packed erythrocyte sediments were washed three times with normal saline and hemolyzed by adding approximately 1.5 volumes of ice-cold distilled water. The stock hemolysate stored at −40 °C for estimation of MDA and GSH levels.

**Statistical Analysis**

The data were analysed by one-way analysis of variance (ANOVA). To compare the difference between the groups, post hoc testing was performed by the Duncan test with least significant difference (LSD). Pearson’s correlation coefficient analysis was used to determine the correlations between different studied parameters. Statistical analysis was performed using the Statistical Package for the Social Science (SPSS) for Windows (version 22.0, Chicago, IL, USA). Data are expressed as mean (SD). Values with $P < 0.05$ were considered statistically significant.

**Results**

The current results revealed that family history, BMI, total cholesterol, LDL-c, and HbA1c levels were significant elevated in recently diagnosed diabetic patients as well as in all treated diabetic groups compared to the healthy control (Table 1). In addition, MCV, MCH and MCHC values showed non-significant changes in all studied groups compared to healthy control. A non-significant lowering in RBCs count was found in all diabetic groups except patients treated with metformin plus insulin [4.89(0.7) vs 4.30(0.5)]. In addition, HCT% revealed a significant decrease in diabetic patients treated with glimepiride therapies compared to the healthy control group. Moreover, Hb concentration was reduced markedly in different diabetic groups, while RDW values had elevated significantly ($P < 0.001$) in all diabetic groups as compared to the healthy control [Figure 1(A)]. While, urinary microalbuminuria was significantly elevated ($P < 0.001$) in all diabetic groups compared to the healthy control [Figure 1(B)]. However, lipid peroxidation biomarker (MDA) was elevated markedly ($P < 0.001$) in all diabetic groups, while the antioxidant GSH level was lowered noticeably ($P < 0.01$) in different diabetic groups when compared to the healthy control ones [Figures 1(C) and 1(D)].
Moreover, HCT value observed a negative significant correlation between HbA1c, microalbuminuria and MDA with metformin monotherapy and combined therapies of metformin. On the other hand, HCT value had a positive significant correlation between GSH with mono-and dual metformin therapies with a sulphonylurea and insulin [0.925 (95% CI: 0.831, 0.975), 0.988 (95% CI: 0.974, 0.997) 0.918 (95% CI: 0.735, 0.991), respectively] [Table 2, Figures 2(C), 2(D), 4(C) and 4(D)]. RDW level showed a significant positive correlation between HbA1c, MDA and microalbuminuria with metformin monotherapy (r; 0.536 (95% CI: 0.935, 0.982, 0.824(95% CI: 0.661, 0.936), respectively) [Table 2, Figures 2(A), 2(B), 4(A) and 4(B)].

| Table 1. Demographic, biochemical and RBC indices in control, recent diabetic and treated diabetic groups |
|-------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| N =                           | Control          | R Diabetic       | Metformin       | Glimepiride     | Metf +Sulf      | Insulin         | Metf+Ins        |
| Gender                        | 50              | 20              | 15              | 19              | 15              | 20              | 19              |
| M ♀                            | 25 (50)a         | 10 (50)a        | 8 (53)c         | 9 (47)c         | 8 (53)c         | 10(52)c         | 13(65)b         |
| F ♂                            | 25 (50)b         | 10 (50)b        | 7(47)c          | 10(53)b         | 7(47)c          | 9(47)b          | 7(35)c          |
| F. hist.                       | (o)c            | 4(20)b          | 6 (40)be        | 5(26)b          | 4(27)b          | 11(58)d         | 8(40)c          |
| Duration (y) M(SD)             | 0.0(0)          | 0.0(0)c         | 4.4(3)b         | 5.8(4)b         | 6.2(5)b         | 16(8)c          | 14(7)c          |
| Age (y)                        | 42(16)           | 49(14)          | 57(8)b          | 63(11)c         | 55(9)c          | 57(8)b          | 62(7)c          |
| BMI                            | 27(7)           | 36(5)b          | 33(7)ab         | 34(4)ab         | 32(8)ab         | 33(10)ab        | 29(4)a          |
| HbA1c%                         | 5.11(0.51)a      | 9.78(1.46)d     | 7.31(1.32)b     | 7.55(1.19)b     | 9.80(2.59)d     | 7.58(1.94)b     | 8.51(2.18)       |
| Creatinine (mg/dL)             | 168(28)b         | 218(48)bc       | 191(51)bc       | 197(55)bc       | 227(41)c        | 194(24)bc       | 220(42)d         |
| TC (mg/dL)                     | 99(38)           | 151(45)bc       | 124(49) ab      | 136(45)bc       | 165(39)4        | 128(23)bc       | 154(39)2         |
| LDL (mg/dL)                    | 14.30(1.0)c      | 12.7(1.9)        | 13.22(0.76)b    | 12.65(1.3)c     | 12.71(0.5)c     | 12.97(1.3)c     | 12.14(1.1)        |
| RBCs (x10⁶/mm³)                | 4.89(0.7)be      | 4.56(0.7)bc     | 4.73(0.3)bc     | 4.50(0.4)ab     | 4.55(0.4)ab     | 4.74(0.5)bc     | 4.30(0.5)         |
| HCT (%)                        | 40.53(3)b        | 37.36(6)ab      | 39.18(2)ab      | 36.65(2)ab      | 38.49(2)ab      | 39.29(5)ab      | 37.12(2)ab        |
| MCV (fl)                       | 83.27(2)ab       | 81.98(7)        | 82.88(5)ab      | 82.14(8)ab      | 85.05(4)ab      | 82.65(6)ab      | 87.15(7)b         |
| MCH (Pg)                       | 28.5(2)          | 27.08(2)        | 27.25(2)        | 27.28(3)        | 28.18(2)        | 27.48(2)        | 28.25(3)          |
| MCHC (g/dL)                    | 13.85(2)b        | 32.90(2)ab      | 31.81(3)        | 33.16(3)b       | 33.07(1)bc      | 32.86(1)ab      | 32.72(1)bc        |

Data are expressed as mean = SD. Values which share the same superscript symbol are not significantly different. R = recent, Metf = metformin, Sulf = sulfonylurea (glimepiride), Ins = insulin, F hist = family history, BMI = body mass index, HbA1c = glycosylated hemoglobin, TC = total cholesterol, LDL = low density lipoprotein, MCV = mean corpuscular volume, MCH = mean corpuscular hemoglobin, MCHC = mean corpuscular hemoglobin concentration

Overall, Hb showed a negative significant correlation with HbA1c, microalbuminuria, and MDA in patients treated with metformin monotherapy [r; −0.778 (95%CI: −0.937, −0.612), r; −0.709 (95% CI: −0.925, −0.475), r; −0.906 (95% CI: −0.971, −0.818), respectively] and dual therapy groups, however, HB observed a positive significant correlation with GSH in all metformin therapy groups [Table 2, Figures 2(A), 2(B), 3(A), 3(B), 5(B) and 5(D)]. Moreover, RBCs count revealed a significant negative correlation with HbA1c, MDA and microalbuminuria in metformin therapies groups. While, RBCs count induced a positive significant correlation with GSH in metformin monotherapy as well as combination therapy groups with a sulphonylurea (glimepiride) and insulin (r; 0.960 (95% CI: 0.935, 0.982, 0.824(95% CI: 0.661, 0.936), respectively) [Table 2, Figures 2(A), 2(B), 4(A) and 4(B)].

Moreover, HCT value observed a negative correlation between HbA1c, microalbuminuria and MDA with metformin monotherapy and combined therapies of metformin. On the other hand, HCT value had a positive significant correlation between GSH with mono-and dual metformin therapies with a sulphonylurea and insulin [0.925 (95% CI: 0.831, 0.975), 0.988 (95% CI: 0.974, 0.997) 0.918 (95% CI: 0.735, 0.991), respectively] [Table 2, Figures 2(C), 2(D), 4(C) and 4(D)]. RDW level showed a significant positive correlation between HbA1c, MDA and microalbuminuria with metformin monotherapy (r; 0.536 (95% CI: 0.082, 0.885), 0.885 (95% CI: 0.596, 0.973), 0.880 (95%CI: 0.563, 0.971), respectively) and dual therapies, while, it correlated negatively with GSH in all tested groups [Table 2, Figures 2(C), 2(D), 3(C), 3(D), 5(A) and 5(C)].
Original Article | Effect of metformin on erythrocytes in diabetes

Figure 1. Values of RDW% (A), microalbuminuria (B), MDA (C) and GSH (D) of control, recent diabetic and different metformin treated groups

*Significance compared to normal control, **P < 0.05, ***P < 0.01, ****P < 0.001, *significance compared to the recent diabetic, **P < 0.05, ***P < 0.01, ****P < 0.001. Metf = metformin, R diabetic = recent diabetic, Sulf = sulfonylurea (glimepiride), Ins = insulin,

Table 2. Pearson correlation of HbA1c, MDA, GSH and microalbuminuria with RBCs indices in different treated groups

|                | HbA1c 95% CI | Microalbuminuria 95% CI | MDA 95% CI | GSH 95% CI |
|----------------|--------------|--------------------------|------------|------------|
| **Metf**       |              |                          |            |            |
| Hb             | −0.778**     | (−0.937, −0.612)         | −0.906**   | (−0.971, −0.818) | 0.884*** (0.802, 0.957) |
| RBCs           | −0.621*      | (−0.905, −0.291)         | −0.867**   | (−0.951, −0.640) | 0.846** (0.579, 0.932) |
| HCT            | −0.713**     | (−0.953, −0.496)         | −0.957**   | (−0.987, −0.914) | 0.925** (0.831, 0.975) |
| RDW            | 0.536*       | (0.082, 0.885)           | 0.885**    | (0.596, 0.973)   | −0.882** (−0.962, −0.532) |
| **Metf + Sulf**|              |                          |            |            |
| Hb             | −0.838**     | (−0.934, −0.562)         | −0.961**   | (−0.985, −0.917) | 0.961** (0.906, 0.990) |
| RBCs           | −0.774**     | (−0.909, −0.563)         | −0.885**   | (−0.973, −0.793) | 0.960** (0.935, 0.982) |
| HCT            | −0.790**     | (−0.926, −0.547)         | −0.917**   | (−0.971, −0.862) | 0.988** (0.974, 0.997) |
| RDW            | 0.888**      | (0.630, 0.965)           | 0.955**    | (0.867, 0.986)   | 0.972** (0.937, 0.991) |
| **Metf + Ins** |              |                          |            |            |
| Hb             | −0.704**     | (−0.192, −0.894)         | −0.831**   | (−0.394, −0.089) | 0.862** (0.973, 0.568) |
| RBCs           | −0.687**     | (−0.855, −0.460)         | −0.721**   | (−0.885, −0.382) | 0.824** (0.661, 0.936) |
| HCT            | −0.688**     | (−0.875, −0.170)         | −0.791**   | (−0.972, −0.325) | 0.918** (0.735, 0.991) |
| RDW            | 0.853**      | (0.092, 0.950)           | 0.865**    | (0.469, 0.957)   | −0.862** (−0.949, −0.549) |

*Correlation is significant at the 0.05 level. **Correlation is significant at the 0.01 level. ***Correlation is significant at the 0.001 level. Metf = metformin, Sulf = sulfonylurea (glimepiride), Ins = insulin, HbA1c = glycosylated hemoglobin
Figure 2. Correlation coefficient of Hb, RBCs, HCT and RDW values with HbA1c% (A), microalbuminuria (B), MDA (C) and GSH (D)

*Correlation is significant at the 0.05 level. **Correlation is significant at the 0.01 level. ***Correlation is significant at the 0.001 level. R = recent, Metf = metformin, R. diabetic = recent diabetic, Sulf = sulfonylurea (glimepiride), Ins = insulin, HbA1c = glycosylated hemoglobin, r = correlation coefficient
**Figure 3.** Correlations of Hg% with HbA1c% (A) and microalbuminuria (B), and RDW with MDA (C) and GSH (D) among metformin monotherapy group

HbA1c = glycosylated hemoglobin, $r$ = correlation coefficient
Figure 4. Correlations between RBCs with MDA (A) and GSH (B), and HCT with HbA1c (C) and microalbuminuria (D) among metformin plus glimepiride group

HbA1c = glycosylated hemoglobin, $r$ = correlation coefficient
Correlations of RDW with HbA1c% (A) and MDA (C), and Hb% with microalbuminuria (B), and GSH (D) among metformin plus insulin patients.

HbA1c = glycosylated hemoglobin, r = correlation coefficient
Discussion

Overall, our results confirmed that Hb concentration was lowered in all diabetic groups, while RDW was elevated significantly in diabetic patients. Also, the erythrocytes (RBCs) count revealed a significant decrease in patients treated with metformin plus insulin. The decrease in RBCs counts in diabetic patients may be due to RBC membrane protein alterations, a decrease in hemoglobin levels and erythropoietin deficiency (13). Hemoglobin is the major component of erythrocytes; thus, when the HbA1c level is elevated, hyperglycemia may increase the β-sheet structure content of Hb causing it to aggregate which subsequently increases WBV (19). In fact, the excessive aggregation of RBC is one of the most prominent features in patients with diabetes with poor glycemic control. The erythrocyte aggregation is an important hemorheological parameter because it directly affects WBV (20). Also, some recent epidemiological studies have reported that T2DM is characterised by increased erythrocyte osmotic fragility (21). In diabetes, erythrocyte membranes are affected by the chronic exposure to glucose, and several biochemical modifications are triggered, with subsequent structural and functional disruption of erythrocytes and decreased the lifespan of RBCs (22) which may be related to RBCs count dimension. Meanwhile, RBC properties are critically affected by hyperglycemia and decreased deformability (23).

Anemia is a highly prevalent condition in people with T2DM. The causes of diabetic anemia are multifactorial including inflammation, concomitant autoimmune diseases, antidiabetic medication, hormonal changes and kidney diseases (12). The manifestation of anemia in diabetics has been attributed to the increase of non-enzymatic glycosylation of RBC membrane proteins, which was correlated with hyperglycemia (24). The protein oxidation and hyperglycemia in diabetics induced an elevation in the production of lipid peroxides that may lead to RBCs hemolysis (25) and subsequently decrease in RBCs count and hemoglobin levels. Moreover, the diabetic and anemic patients had high levels of C-reactive protein and ferritin ultra-sensitive with low iron contents which might refer to association between ferritin increase and chronic inflammatory process in diabetics (26). However, long-term treatment with metformin is known to be associated with vitamin B12 deficiency and anemia in patients with T2DM (27, 28). It is reported that long-term use of metformin was associated with biochemical B12 deficiency and anemia (28). Since vitamin B12 is essential to nutrition, the metformin-induced B12 reduction may have detrimental effects in patients with T2DM (29). Moreover, Kang et al. recommended the need for regular vitamin B12 monitoring in patients with T2DM, particularly patients receiving a higher daily dosage of sulfonylurea plus metformin treatment for a long time period (27).

The main pathophysiological consequences of free radical-induced lipid peroxidation are disturbing the assembly of cell membranes, which inevitably will impact membrane fluidity, and lipid-protein interaction dynamics, membrane permeability, and physicochemical properties (30). Moreover, in this study, MDA concentration was elevated markedly in all diabetic groups, while, the GSH level was lowered significantly in diabetic subjects. In addition, RBCs count, Hb and HCT values showed a negative correlation between HbA1c, MDA and microalbuminuria with metformin therapies. However, a positive correlation with GSH in all diabetic groups was observed. Hyperlipidemia and increased lipid peroxidation were strongly associated with increased systemic inflammation, and as well as the increased MDA production has also been recorded in the erythrocyte membrane of diabetic patients (8). Additionally, in parallel with our findings, De Souza Bastos et al. suggested that diabetes was associated with dyslipidemia and increased lipid peroxidation (31). Moreover, Lee et al. concluded that the high level of lipids may alter the morphology and flow behaviour of RBCs, which could contribute to the impairment of microcirculatory-related disorders (32).

In addition, in accordance with the current study, several findings showed that patients with T2DM had lower GSH content in erythrocytes than that in the control group. Also, a decrease in intracellular glutathione level in patients with T2DM was reported especially in the presence of microvascular complications (33), which was depend on the degree of hyperglycemia. Furthermore, patients with T2DM have a lower concentration of intracellular GSH, which increase the susceptibility of blood cells to the damaging effects of ROS. Wagliaiah and Alzohairy found a significant impact of oxidative stress (low glutathione) on glutathione peroxidase which could reduce Hb concentration.
Original Article | Effect of metformin on erythrocytes in diabetes

in diabetic patients, which means that oxidative stress of diabetes is one of the causes of anemia in diabetics independently from diabetic nephropathy (34).

In accordance with our results, the RDW values were significantly higher in diabetic patients than that of healthy subjects (35). Furthermore, the RDW level showed a positive correlation with HbA1c, MDA and microalbuminuria in all metformin administered therapies. The exact pathophysiological mechanism underlying the association between RDW and diabetes still unknown, however, it was established that inflammation and oxidative stress can alter erythrocyte homeostasis and increase RDW values. Although the specific mechanisms between the RDW and adverse health outcomes were fully unclear, it was suggested that it could be related to increased oxidative stress and inflammatory cytokines (36). Inflammation inhibits bone marrow function and iron metabolism, and pro-inflammatory cytokines have been proven to inhibit erythropoietin-induced maturation and proliferation of erythrocytes. All these factors may contribute to the increase in RDW% (37). Additionally, high RDW indicated impairment of erythropoiesis, reflecting chronic inflammation and increased level of oxidative stress, both of which were significant signs of T2DM (38). As we all know, diabetes mellitus is considered as a chronic inflammatory disease (39). Thus, the achievement of the glycemic remission might result from a lower level of inflammation and oxidative stress which was indicated by lowering the RDW level. Increased RDW value was therefore reflect the significant deregulation of erythrocyte homeostasis. This deregulation induced chronic inflammation, the elevation of oxidative stress, erythrocyte fragmentation, poor nutritional status, hypertension, dyslipidemia, impairment of erythropoiesis, and erythropoietin dysfunction (15).

Microalbuminuria, the best sign for diabetic nephropathy development in T2DM, was also, accepted as an indicator of diabetic microangiopathy (40). Urinary microalbuminuria, in this study, was significantly increased in all treated diabetic groups. The erythropoietin dysregulation, caused by early damage to renal tubules, has been suggested as one of the contributors to anemia in patients with diabetes (41). Magri and Fava found that RDW was strongly associated with diabetic nephropathy and may be independently associated with microalbuminuria in patients with T2DM (42). Some investigators attributed the association between RDW and microalbuminuria to the presence of chronic inflammation in diabetics (43).

When fructose-fed rats were treated with metformin, the imbalance between peroxidation and antioxidants defense system was mitigated (44). However, treatment with glimepiride and vildagliptin improved erythrocyte deformability in patients with T2DM, the improvement seemed to be correlated with improved glycemic control (45). Moreover, it was observed that patients of good glycemic control have lower RDW than the patients of poor control (35). On the other hand, metformin or glibenclamide might ameliorate oxidative stress in the kidneys of diabetic rats to a certain extent with regard to SOD and MDA (46). Tessier et al. reported that the improved glycemic control with gliclazide and metformin therapy was associated with improvement in the antioxidant/lipid peroxidation status (47). In addition, Chukwunonso-Obi et al. found that administration of metformin, glibenclamide, and repaglinide exhibited a significant reduction in MDA concentration and considerable improvement in the altered activities of antioxidant enzymes (48).

Conclusion

The data indicated that metformin administration can induce amelioration in hyperglycemia and oxidative stress as well as inflammation status regarded to MDA, GSH and RDW levels. However, Hb concentration showed a reduction in metformin-treated groups in spite of improvements in glycemic and oxidative status. This mean that the metformin-induced anemia is independent of diabetes.

Acknowledgements

None.

Conflict of Interest

None.

Funds

None.
Authors’ Contributions

Conception and design: AAM, ESA-R, MS
Analysis and interpretation of the data: WA
Drafting of the article: AAM, ESA-R
Critical revision of the article for important intellectual content: AAM
Final approval of the article: AAM, ESA-R, MS, WA
 Provision of study materials or patients: WA
Statistical expertise: WA
Administrative, technical, or logistic support: ESA-R
Collection and assembly of data: WA

Correspondence

Professor Dr Adel Abdel Moneim
PhD (University of Cairo), MSc (University of Cairo)
Molecular Physiology Division,
Faculty of Science, Beni-Suef University,
Salah Salem St, 62511, Beni Suef, Egypt.
Tel: +2 01006 5451764
Fax: +2 082 2356845
E-mail: adel_men2020@yahoo.com & adel.hassan@science.bsu.edu.eg

References

1. Matheus AS, Tannus LR, Cobas RA, Palma CC, Negrato CA, Gomes MB. Impact of diabetes on cardiovascular disease: an update. Int J Hypertens. 2013;2013:653789. https://doi.org/10.1155/2013/653789
2. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137–149. https://doi.org/10.1016/j.diabres.2013.11.002
3. American diabetic association (ADA). Standards of medical care in diabetes—2012, American Diabetes Association. Diabetes Care. 2012;35(Suppl 1):S11–S63. https://doi.org/10.2337/dc12-0111
4. Bouchoucha M, Uzzan B, Cohen R. Metformin and digestive disorders. Diabetes Metab. 2011;37(2):90–96. https://doi.org/10.1016/j.diabet.2010.11.002
5. Basit A, Riaz M, Fawwad A. Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected]. Vasc Health Risk Manag. 2012;8(4):463–472. https://doi.org/10.2147/VHRM.S33194
6. Yuan T, Yang T, Chen H, Fu D, Hu Y, Wang J, et al. New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis. Redox Biol. 2018;20:247–260. https://doi.org/10.1016/j.redox.2018.09.025
7. Gawlik K, Naskalski JW, Fedak D, Pawlica-Gosiewska D, Grudzień U, Dumnicka P, et al., Markers of antioxidant defense in patients with type 2 diabetes. Oxid Med Cell Longev. 2015;2016:2352361. https://doi.org/10.1155/2016/2352361
8. Kumawat M, Sharma TK, Singh I, Singh N, Ghalaut VS, Vardey SK, et al. Antioxidant enzymes and lipid peroxidation in type 2 diabetes mellitus patients with and without nephropathy. N Am J Med Sci. 2013;5(3):213–219. https://doi.org/10.4103/1947-2714.109193
9. Comazzi S, Spagnolo V, Bonfanti U. Erythrocyte changes in canine diabetes mellitus: in vitro effects of hyperglycaemia and ketoacidosis. Comp Clin Pathol. 2004;12(4):199–205. https://doi.org/10.1007/s00580-004-0502-x
10. Demirtas L, Degirmenci H, Akbas EM, Ozcicek A, Timuroglu A, Gurel A, et al. Association of hematological indices with diabetes, impaired glucose regulation and microvascular complications of diabetes. Int J Clin Exp Med. 2015;8(7):11420–11427.
11. Barbieri J, Fontela PC, Winkelmann ER, Zimmermann CE, Sandri YP, Mallet EK, et al. Anemia in patients with type 2 diabetes mellitus. Anemia. 2015;2015:354737. https://doi.org/10.1007/10.00580-004-0502-x
12. Hosseini MS, Rostami Z, Saadat A, Saadatmand SM, Naeimi E. Anemia and microvascular complications in patients with type 2 diabetes mellitus. Nephrourol Mon. 2014;6(4):e19976. https://doi.org/10.5812/numonthly.19976
13. Wang Z-S, Song Z-C, Bai J-H, Li F, Wu T, Qi J, et al. Red blood cell count as an indicator of microvascular complications in Chinese patients with type 2 diabetes mellitus. Vasc Health Risk Manag. 2013;9:237–243. https://doi.org/10.2147/VHRM.S43211
14. Cho Yi, Mooney MP, Cho DJ. Hemorheological disorders in diabetes mellitus. J Diabetes Sci Tech. 2008;2(6):1130–1138. https://doi.org/10.1177/193229680800200622
Original Article | Effect of metformin on erythrocytes in diabetes

15. Salvagno GL, Sanchis-Gomar F, Picanza A, Lippi G. Red blood cell distribution width: a simple parameter with multiple clinical applications. Crit Rev Clin Lab Sci. 2015;52(2):86–105. https://doi.org/10.3109/10408363.2014.92064

16. Cakir L, Aktas G, Enginyurt O, Cakir SA. Mean platelet volume increases in type 2 diabetes mellitus independent of HbA1c level. Acta Medica Mediterranea. 2014;30:425–428.

17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemist. 1972;18(6):499–502.

18. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362(6423):801–809. https://doi.org/10.1038/362801a0

19. Chalew SA, McCarter RJ, Hempe JM. Biological variation and hemoglobin A1c: relevance to diabetes management and complications. Pediatr Diabetes. 2013;14(6):391–398. https://doi.org/10.1111/pedi.12055

20. Kim S, Popel AS, Intaglietta M, Johnson PC. Effect of erythrocyte aggregation at normal human levels on functional capillary density in rat spinotrapezius muscle. Am J Physiol Heart Circ Physiol. 2006;290(3):H941–H947. https://doi.org/10.1152/ajpheart.00645.2005

21. Lippi G, Mercadanti M, Aloe R, Targher G. Erythrocyte mechanical fragility is increased in patients with type 2 diabetes. Eur J Intern Med. 2012;23(2):150–153. https://doi.org/10.1016/j.ejim.2011.11.004

22. Gabreanu GR, Angelescu S. Erythrocyte membrane in type 2 diabetes mellitus. Discoveries. 2016;4(2):e60. https://doi.org/10.15190/d.2016.7

23. Agrawal R, Smart T, Cardoso J, Richards C, Bhatnagar R, Tufail A, et al. Assessment of red blood cell deformability in type 2 diabetes mellitus and diabetic retinopathy by dual optical tweezers stretching technique. Sci Rep. 2016;6:15873. https://doi.org/10.1038/srep15873

24. Oyedemi S, Yakuibu M, Afolayan A. Antidiabetic activities of aqueous leaves extract of Leonotis leonurus in streptozotocin induced diabetic rats. J Med Plants Res. 2011;5:119–125.

25. Shenoy AG, Goyal RK. Improvement of insulin sensitivity by perindopril in spontaneously hypertensive and streptozotocin-diabetic rats. Indian J Pharmacol. 2002;34:156–164.

26. Andrews M, Arredondo M. Ferritin levels and hepcidin mRNA expression in peripheral mononuclear cells from anemic type 2 diabetic patients. Biological Trace Element Research. 2012;149(1):1–4. https://doi.org/10.1007/s12011-012-9389-6

27. Kang D, Yun J-S, Ko S-H, Lim T-S, Ahn Y-B, Park Y-M, et al. Higher prevalence of metformin-induced vitamin B12 deficiency in sulfonylurea combination compared with insulin combination in patients with type 2 diabetes: a cross-sectional study. PLoS One. 2014;9(10):e109878. https://doi.org/10.1371/journal.pone.0109878

28. Aroda VR, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, et al. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101(4):1754–1761. https://doi.org/10.1210/jc.2015-3754

29. Liu Q, Li S, Quan H, Li J. Vitamin B12 status in metformin treated patients: systematic review. PLoS One. 2014;9(6):e100379. https://doi.org/10.1371/journal.pone.0100379

30. Volinsky R, Kinnunen PK. Oxidized phosphatidylcholines in membrane-level cellular signaling from biophysics to physiology and molecular pathology. FEBS J. 2013;280(12):2806–2816. https://doi.org/10.1111/febs.12247

31. de Souza Bastos A, Graves DT, de Melo Loureiro AP, Júnior CR, Corbi SCT, Frizzera F, et al. Diabetes and increased lipid peroxidation are associated with systemic inflammation even in well-controlled patients. J Diabetes Complications. 2016;30(2):1593–1599. https://doi.org/10.1016/j.jdiacomp.2016.07.011

32. Lee C-YJ, Kim K-C, Park H-W, Song J-H, Lee C-H. Rheological properties of erythrocytes from male hypercholesterolemia. Microvasc Res. 2004;67(2):133–138. https://doi.org/10.1016/j.mvr.2003.12.006
33. Lutchmansingh FK, Hsu JW, Bennett FI, Badaloo AV, McFarlane-Anderson N, Gordon-Strachan GM, et al. Glutathione metabolism in type 2 diabetes and its relationship with microvascular complications and glycemia. *PloS One*. 2018;13(6):e0198626. https://doi.org/10.1371/journal.pone.0198626

34. Waggiallah H, Alzohairy M. The effect of oxidative stress on human red cells glutathione peroxidase, glutathione reductase level, and prevalence of anemia among diabetics. *N Am J Med Sci*. 2011;3(7):344–347. https://doi.org/10.4297/najms.2011.3344

35. Nada AM. Red cell distribution width in type 2 diabetic patients. *Diabetes Metab Syndr Obes*. 2015;2015:525–533. https://doi.org/10.2147/DMSO.S85318

36. Lippi G, Targarher G, Montagnana M, Salvagno GL, Zoppini G, Guidi GC. Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients. *Arch Pathol Lab Med*. 2009;133:628–632.

37. Osterholm EA, Georgieff MK. Chronic inflammation and iron metabolism. *J Pediatr*. 2015;166(6):1351–1357. https://doi.org/10.1016/j.jpeds.2015.01.017

38. Dada OA, Uche E, Akinbami A, Odesanya M, John-Olabode S, Adediran A, et al. The relationship between red blood cell distribution width and blood pressure in patients with type 2 diabetes mellitus in Lagos, Nigeria. *J Blood Med*. 2014;5:185–189. https://doi.org/10.2147/JBM.S67989

39. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. *Nat Rev Immunol*. 2011;11:98–107. https://doi.org/10.1038/nri2925

40. Ünübol M, Ayhan M, Güney E. The relationship between mean platelet volume with microalbuminuria and glycemic control in patients with type II diabetes mellitus. *Platelets*. 2012;23(6):475–480. https://doi.org/10.3109/09537104.2011.634934

41. Dikow R, Schwenger V, Schömig M, Ritz E. How should we manage anaemia in patients with diabetes? *Nephrol Dial Transplant*. 2002;17(Suppl 1):67–72. https://doi.org/10.1093/ndt/17.suppl_1.67

42. Magri CJ, Fava S. Red blood cell distribution width and diabetes-associated complications. *Diabetes Metab Syndr: Clin Res Rev*. 2014;8(1):13–17. https://doi.org/10.1016/j.dsx.2013.10.012

43. Zhang M, Zhang Y, Li C, He L. Association between red blood cell distribution and renal function in patients with untreated type 2 diabetes mellitus. *Ren Fail*. 2015;37(4):659–663. https://doi.org/10.3109/0886022X.2015.1010938

44. Srividhya S, Ravichandran M, Anuradha C. Metformin attenuates blood lipid peroxidation and potentiates antioxidant defense in high fructose-fed rats. *J Biochem Mol Biol Biophys*. 2002;6:379–385. https://doi.org/10.1080/1025814021000024280

45. Berndt-Zipfel C, Michelson G, Dworak M, Mitry M, Löffler A, Pfützner A, et al. Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus–results from an exploratory study. *Cardiovasc Diabetol*. 2013;12:59. https://doi.org/10.1186/1475-2840-12-59

46. Erejuwa OO, Sulaiman SA, Wahab MSA, Salam SKN, Salleh MSM, Gurtu S. Comparison of antioxidant effects of honey, glibenclamide, metformin, and their combinations in the kidneys of streptozotocin-induced diabetic rats. *Int J mol Sci*. 2011;12(1):829–843. https://doi.org/10.3390/ijms12010829

47. Tessier D, Maheux P, Khalil A, Fülöp T. Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes. *Metabolism*. 1999;48(7):897–903. https://doi.org/10.1016/S0026-0495(99)90226-3

48. Chukwunonso Obi B, Chinwuba Okoye T, Okpashi VE, Nonye Igwe C, Olisah Alumanah E. Comparative study of the antioxidant effects of metformin, glibenclamide, and repaglinide in alloxan-induced diabetic rats. *J Diabetes Res*. 2015;2016:1635361. http://doi.org/10.1155/2016/1635361